Chinook Therapeutics, Inc. (NASDAQ: KDNY) and Evotec SE today
announced a strategic collaboration focused on the discovery and
development of novel precision medicine therapies for patients with
chronic kidney diseases. Based on Evotec’s proprietary
comprehensive molecular datasets from thousands of patients across
chronic kidney diseases of multiple underlying etiologies, Chinook
and Evotec will jointly identify, characterize and validate novel
mechanisms and discover precision medicines for PKD, lupus
nephritis, IgA nephropathy and other primary glomerular diseases.
The collaboration will also involve further characterization of
pathways and patient stratification strategies for programs
currently in Chinook’s clinical and preclinical pipeline.
“We are excited to embark on this strategic collaboration with
Evotec, the leading drug discovery alliance and development partner
in nephrology,” said Andrew King, D.V.M., Ph.D., Head of Renal
Discovery and Translational Medicine at Chinook. “Gaining access to
the NURTuRE cohort study and other proprietary patient biobanks,
along with Evotec’s multi-omics integration platform, will enable
us to define the molecular drivers of kidney diseases, identify
novel targets for drug development in selected patient
sub-populations and continue to build the foundation for our
precision medicine approach. With a focus on comprehensive
molecular disease classification, combined with prospective
clinical outcomes, Chinook has the opportunity to potentially
deliver targeted therapies to the right patient populations.”
The National Unified Renal Translational Research Enterprise
(NURTuRE) is the first biobank for chronic kidney diseases and
nephrotic syndrome (NS), covering England, Scotland and Wales.
Biological samples, including plasma, serum, urine, DNA and kidney
biopsies, from 3,000 patients with chronic kidney diseases and over
800 patients with NS from 18 NHS Trusts, are being collected and
stored under strict standards for academic and industrial research
globally. NURTuRE also has the advantage of containing anonymized
linked clinical data through the U.K. Renal Registry, which will
enable the development of new prognostic and predictive biomarkers.
This will potentially allow Chinook and Evotec to identify patients
who will benefit from better, earlier diagnosis and individualized
new treatments, resulting in improved health outcomes.
The collaboration also leverages Evotec’s proprietary PanOmics
platform, which combines enhanced throughput proteomics, high
throughput transcriptomics and cell imaging with PanHunter,
Evotec’s unique data analysis platform.
“We are glad to enter into a discovery and development
partnership with Chinook Therapeutics, a company specializing in
overcoming kidney diseases. CKD is a collective term for a variety
of diseases that cause a gradual loss of kidney function. The
diversity in the underlying causes makes this area especially
favorable for data-driven and systematically personalized
approaches,” said Cord Dohrmann, Ph.D., Chief Scientific Officer of
Evotec. “By leveraging our complementary platforms, Evotec and
Chinook have the best possible starting position to tackle
particular rare forms of CKD with the goal to develop
disease-modifying therapeutics for underserved patient
populations.”
Under the terms of the agreement, Chinook and Evotec will share
drug discovery and preclinical development responsibilities.
Chinook will be responsible for clinical development and
commercialization of product candidates developed under the
collaboration. Evotec will receive an undisclosed upfront payment,
research funding, progress-dependent milestone payments and tiered
royalties on net sales for targets identified through the
collaboration.
About Chinook Therapeutics, Inc.Chinook
Therapeutics, Inc. is a clinical-stage biotechnology company
developing precision medicines for kidney diseases. Chinook’s
product candidates are being investigated in rare, severe chronic
kidney disorders with opportunities for well-defined clinical
pathways. Chinook’s lead program is atrasentan, an investigational
phase 3 endothelin receptor antagonist for the treatment of IgA
nephropathy and other primary glomerular diseases. BION-1301, an
investigational anti-APRIL monoclonal antibody, is being evaluated
in a phase 1b trial for IgA nephropathy. In addition, Chinook is
advancing CHK-336, an investigational oral small molecule LDHA
inhibitor for the treatment of primary hyperoxaluria, as well as
research programs for other rare, severe chronic kidney diseases,
including polycystic kidney disease. Chinook is building its
pipeline by leveraging insights in kidney single cell RNA
sequencing, human-derived organoids and new translational models,
to discover and develop therapeutics with differentiating
mechanisms of action against key kidney disease pathways. To learn
more, visit www.chinooktx.com.
About Evotec SE Evotec is a drug discovery
alliance and development partnership company focused on rapidly
progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient
advocacy groups and venture capitalists. Evotec operates worldwide
and our more than 3,500 employees provide the highest quality
stand-alone and integrated drug discovery and development
solutions. Evotec cover all activities from target-to-clinic to
meet the industry’s need for innovation and efficiency in drug
discovery and development (EVT Execute). The Company has
established a unique position by assembling top-class scientific
experts and integrating state-of-the-art technologies as well as
substantial experience and expertise in key therapeutic areas
including neuronal diseases, diabetes and complications of
diabetes, pain and inflammation, oncology, infectious diseases,
respiratory diseases, fibrosis, rare diseases and women’s health.
On this basis, Evotec has built a broad and deep pipeline of more
than 100 co-owned product opportunities at clinical, pre-clinical
and discovery stages (EVT Innovate). Evotec has established
multiple long-term alliances with partners including Bayer,
Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo
Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional
information please go to www.evotec.com and follow us on Twitter
@Evotec.
Cautionary Note on Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, including those relating to Chinook’s business, future
operations, advancement of its product candidates and product
pipeline, clinical development of its product candidates, including
expectations regarding timing of initiation and results of clinical
trials. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “expect” or the
negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, our ability to develop and
commercialize our product candidates, including initiation of
clinical trials of our existing product candidates or those
developed as part of the Evotec collaboration, whether results of
early clinical trials or preclinical studies will be indicative of
the results of future trials, our ability to obtain and maintain
regulatory approval of our product candidates, our ability to
operate in a competitive industry and compete successfully against
competitors that may be more advanced or have greater resources
than we do, our ability to obtain and adequately protect
intellectual property rights for our product candidates and the
effects of COVID-19 on our clinical programs and business
operations. Many of these risks are described in greater detail in
our filings with the SEC. Any forward-looking statements in this
press release speak only as of the date of this press release.
Chinook assumes no obligation to update forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
Contact:Noopur LiffickVice President, Investor
Relations & Corporate Communicationsinvestors@chinooktx.com
media@chinooktx.com
Chinook Therapeutics (NASDAQ:KDNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chinook Therapeutics (NASDAQ:KDNY)
Historical Stock Chart
From Sep 2023 to Sep 2024